Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands

References

• Bower H, Bjorkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–2857.
   PubMed Web of Science ®Google Scholar
• Ector G, Visser O, Westerweel PE, et al. Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in The Netherlands, 1989–2017. Leukemia. 2020;34(12):3408–3412.
   PubMed Web of Science ®Google Scholar
• Viganò I, Di Giacomo N, Bozzani S, et al. First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis. Am J Hematol. 2014;89(10):E184–E187.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Antolini L, Mahon F-X, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103(7):553–561.
   PubMedGoogle Scholar
• Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809–1820.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984.
   PubMed Web of Science ®Google Scholar
• Deininger MW, Shah NP, Altman JK, et al. Chronic myeloid leukemia. J Natl Compr Canc Netw. 2020;18(10):1385–1415.
   PubMed Web of Science ®Google Scholar
• Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence – what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–2297.
   PubMed Web of Science ®Google Scholar
• Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110(3):551–555.
   PubMed Web of Science ®Google Scholar
• Mauro MJ, Davis C, Zyczynski T, et al. The role of observational studies in optimizing the clinical management of chronic myeloid leukemia. Ther Adv Hematol. 2015;6(1):3–14.
   PubMedGoogle Scholar
• Webster J, Smith BD. The case for real-world evidence in the future of clinical research on chronic myeloid leukemia. Clin Ther. 2019;41(2):336–349.
   PubMed Web of Science ®Google Scholar
• Rohrbacher M, Berger U, Hochhaus A, et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia. 2009;23(3):602–604.
   PubMed Web of Science ®Google Scholar
• Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol. 2009;22(3):295–302.
   PubMed Web of Science ®Google Scholar
• Brunner AM, Campigotto F, Sadrzadeh H, et al. Trends in all-cause mortality among patients with chronic myeloid leukemia: a surveillance, epidemiology, and end results database analysis. Cancer. 2013;119(14):2620–2629.
   PubMed Web of Science ®Google Scholar
• Geelen IGP, Thielen N, Janssen J, et al. Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival. Haematologica. 2017;102(12):e486–e489.
   PubMed Web of Science ®Google Scholar
• Hillis CM, Busque L, Stakiw J, et al. Adherence to chronic myeloid leukemia monitoring and treatment guidelines in Canadian registries. Blood. 2016;128(22):3079.
   Web of Science ®Google Scholar
• Saleh MN, Haislip S, Sharpe J, et al. Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting. Curr Med Res Opin. 2014;30(4):529–536.
   PubMed Web of Science ®Google Scholar
• Chen L, Guerin A, Xie J, et al. Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis. Curr Med Res Opin. 2012;28(11):1831–1839.
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Chen L, Guerin A, et al. Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib. Curr Med Res Opin. 2013;29(9):1075–1082.
   PubMed Web of Science ®Google Scholar
• Jackson J, Chen L, Sail KR, et al. Monitoring patterns and subsequent outcomes among patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph + CML) treated with imatinib in a community setting. Blood. 2012;120(21):2066.
   Web of Science ®Google Scholar
• Guerin A, Chen L, Dea K, et al. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Curr Med Res Opin. 2014;30(7):1345–1352.
   PubMed Web of Science ®Google Scholar
• Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, et al. Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency. J Manag Care Spec Pharm. 2017;23(2):214–224.
   PubMed Web of Science ®Google Scholar
• Guérin A, Chen L, Dea K, et al. Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia. J Med Econ. 2014;17(2):89–98.
   PubMedGoogle Scholar
• Campbell SM, Braspenning J, Hutchinson A, et al. Research methods used in developing and applying quality indicators in primary care. BMJ. 2003;326(7393):816–819.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ. 2008;336(7652):1049–1051.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48–56.
   PubMed Web of Science ®Google Scholar
• Sokal JE, Gomez GA, Baccarani M, et al. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood. 1988;72(1):294–298.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–884.
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Akard LP, Dugan MJ, et al. Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemia. J Oncol Pract. 2015;11(3):e398–e404.
   PubMed Web of Science ®Google Scholar
• Saussele S, Krauss MP, Hehlmann R, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 2015;126(1):42–49.
   PubMed Web of Science ®Google Scholar
• Branford S, Yeung DT, Parker WT, et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014;124(4):511–518.
   PubMed Web of Science ®Google Scholar
• Shanmuganathan N, Pagani IS, Ross DM, et al. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood. 2021;137(9):1196–1207.
   PubMed Web of Science ®Google Scholar
• Shanmuganathan N, Braley JA, Yong ASM, et al. Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. Blood. 2019;134(1):85–89.
   PubMed Web of Science ®Google Scholar
• Milojkovic D, Cross NCP, Ali S, et al. Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. Br J Haematol. 2021;192(1):62–74.
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Cortes JE, Gambacorti-Passerini C, et al. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2017;92(11):1214–1223.
   PubMed Web of Science ®Google Scholar
• Schünemann HJ, Fretheim A, Oxman AD. Improving the use of research evidence in guideline development: 13. Applicability, transferability and adaptation. Health Res Policy Syst. 2006;4:25.
   PubMedGoogle Scholar
• Carey M, Buchan H, Sanson-Fisher R. The cycle of change: implementing best-evidence clinical practice. Int J Qual Health Care. 2009;21(1):37–43.
   PubMed Web of Science ®Google Scholar
• Bilimoria KY. Facilitating quality improvement: pushing the pendulum back toward process measures. JAMA. 2015;314(13):1333–1334.
   PubMed Web of Science ®Google Scholar
• Goldberg SL. Monitoring chronic myeloid leukemia in the real world: gaps and opportunities. Clin Lymphoma Myeloma Leuk. 2015;15(12):711–714.
   PubMed Web of Science ®Google Scholar
• Bilimoria KY, Bentrem DJ, Lillemoe KD, et al. Assessment of pancreatic cancer care in the United States based on formally developed quality indicators. J Natl Cancer Inst. 2009;101(12):848–859.
   PubMedGoogle Scholar
• Bilimoria KY, Raval MV, Bentrem DJ, et al. National assessment of melanoma care using formally developed quality indicators. J Clin Oncol. 2009;27(32):5445–5451.
   PubMed Web of Science ®Google Scholar
• Ouwens M, Hermens R, Termeer RAR, et al. Quality of integrated care for patients with nonsmall cell lung cancer. Cancer. 2007;110(8):1782–1790.
   PubMed Web of Science ®Google Scholar
• van Overveld LF, Braspenning JC, Hermens RP. Quality indicators of integrated care for patients with head and neck cancer. Clin Otolaryngol. 2017;42(2):322–329.
   PubMed Web of Science ®Google Scholar
• Wennekes L, Ottevanger PB, Raemaekers JM, et al. Development and measurement of guideline-based indicators for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2011;29(11):1436–1444.
   PubMed Web of Science ®Google Scholar